Project Grant R01HL179623
Award Date 9/1/25
Completion Date 6/30/29
Dollars Obligated $702K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Aurora, CO 80045, USA
Similar Awards
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is for $249,000.00 to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) from August 1, 2025 to July 31, 2028. The objective of this research is to improve the mechanistic understanding of mucin biology, particularly the polymerization and trafficking mechanisms of mucin from the endoplasmic reticulum to the Golgi. The research aims to employ mouse...
- The University of Maryland, College Park received a $711,144 project grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to conduct research on the role of glycan-mediated interactions in the mucus barrier's ability to neutralize diverse respiratory viruses, including influenza A, rhinovirus, and respiratory syncytial virus. The project aims to determine how mucin-associated glycans dictate the structural properties and mucociliary clearance of...
- The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $189,000 Project Grant under CFDA #93.837 Cardiovascular Diseases Research program to the University of Colorado-Denver. The 2-year grant, with a period of performance from September 15, 2025 to August 31, 2027, will support research to investigate the role of outdoor air pollution and environmental allergens in driving treatment response in children with acute asthma...
- This $387,116 Project Grant award from the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) supports research at the University of South Florida to investigate the sensory neuronal mechanisms underlying the development of house dust mite-induced airway hyperreactivity, a key characteristic of asthma. The long-term goal is to define the neural mechanisms triggered by house dust mite exposure that lead to the development of airway...
- This $1,392,946 Project Grant awarded on July 20, 2025 by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will support research at the University of Pittsburgh to investigate the role of microbial-derived metabolites in driving airway hyperresponsiveness in obesity-associated asthma. The project aims to elucidate how dysregulated bile acid metabolism and gut dysbiosis instigate obesity-related asthma through alterations in the unfolded protein...
- The University of New Mexico was awarded a $522,990 Project Grant under the National Institutes of Health (NIH) National Heart, Lung, and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837). The grant, awarded on September 1, 2025, will support research to elucidate the mechanisms underlying the counter-regulation of allergic airway inflammation by regulating the responsiveness of Group 2 Innate Lymphoid Cells (ILC2s). The proposed studies aim to address the knowledge gap in...
- The Washington University was awarded a $761,782 Project Grant from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) on September 1, 2025, with a completion date of July 31, 2029. The grant supports comprehensive research to investigate the cellular processes resulting in acquired airway ciliopathies, which are characterized by loss of cilia maintenance and impaired airway clearance observed in lung diseases such as asthma and COPD. Key objectives...
- This federal Project Grant award, totaling $756,875.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Cincinnati. The award supports research to investigate the fundamental mechanisms by which neutrophil extracellular traps (NETs) contribute to airway damage and infection in mucoobstructive lung diseases, such as cystic fibrosis. Key research aims include examining how NET-mediated...
- The National Heart, Lung, and Blood Institute (NHLBI), via the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $564,445 Project Grant to the University of Texas Health Science Center at Houston (UTHealth) to fund research on "Targeting Hypoxia-Inducible Factors (HIFs) for Heart and Lung Disease." The 6-year grant, starting on March 1, 2025 and ending on December 31, 2031, supports three complementary research projects focused on investigating the upstream regulation...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $169,560 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Regents of the University of Michigan. This 5-year career development grant is intended to support Dr. Tayyab Rehman's research to enhance airway host defense mechanisms, with the goal of improving outcomes for individuals with bronchiectasis. The research plan focuses on understanding how modulating the WNK1 protein in airway epithelial...